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Abstract: Radiation-induced lung injury (RILI) is the most com-
mon, dose-limiting complication of thoracic radio- and radiochemo-
therapy. Unfortunately, predicting which patients will suffer from
this complication is extremely difficult. Ideally, individual pheno-
type- and genotype-based risk profiles should be able to identify
patients who are resistant to RILI and who could benefit from dose
escalation in chemoradiotherapy. This could result in better local
control and overall survival. We review the risk predictors that are
currently in clinical use—dosimetric parameters of radiotherapy
such as normal tissue complication probability, mean lung dose,
V20 and V30—as well as biomarkers that might individualize risk
profiles. These biomarkers comprise a variety of proinflammatory
and profibrotic cytokines and molecules including transforming
growth factor 1 that are implicated in development and persis-
tence of RILI. Dosimetric parameters of radiotherapy show a low
negative predictive value of 60% to 80%. Depending on the
studied molecule, negative predictive value of biomarkers is
approximately 50%. The predictive power of biomarkers might
be increased if they are coupled with radiogenomics, e.g., geno-
typing analysis of single nucleotide polymorphisms in transform-
ing growth factor 1, transforming growth factor 1 pathway
genes, and other cytokines. Genetic variability and the complex-
ity of RILI and its underlying molecular mechanisms make
identification of biological risk predictors challenging. Further
investigations are needed to develop more effective risk predic-
tors of RILI.
Key Words: Radiation-induced lung injury, Patient-specific predic-
tion, Biological markers, Transforming growth factor 1, Single
nucleotide polymorphism.
(J Thorac Oncol. 2007;2: 864–874)
Radiation pneumonitis (RP) and pulmonary fibrosis (PF)represent acute and late phases in development of radia-
tion-induced lung injury (RILI). Distinction between these
phases is arbitrary because early and late effects of ionizing
radiation on normal tissues constitute a continuous spectrum
of biological events.1 For thoracic radiotherapy, RP and PF
present the most common and the major, sometimes fatal,
dose-limiting toxicities. Onset of RP occurs 1 to 6 months
after treatment, whereas PF develops gradually months to
years later. Diagnosis of RP is based on nonspecific symp-
toms of dyspnea, cough, occasional fever, and chest pain with
or without abnormalities in pulmonary function tests. Post-
treatment radiographic changes may reveal infiltration inside
(local RP) or outside the irradiation field (diffuse RP), occa-
sionally affecting the contralateral lung. In approximately
28% of RP patients, the diagnosis is uncertain due to con-
founding factors.2 PF develops in almost all patients receiv-
ing radiotherapy.3 It is detected radiographically through
permanent scarring of the lung tissue. PF patients may have
varying degrees of dyspnea, cough, and chest pain or present
no symptoms.
Although RP typically subsides over time, PF may
progress and become irreversible. Radiographic examination
of breast cancer patients who received radiotherapy showed a
peak of increased lung density after 6 months, followed by a
decrease and a late stable situation after 12 to 18 months.4
Progressive increase in lung density for the next 5 to 6 years
was seen in only 7.7% of these patients. Because such a long
period of follow-up is unlikely in the majority of lung cancer
patients, Bentzen et al.5 proposed a minimum of 1 to 2 years
for the assessment of late RILI.
Histopathology suggests a three-step process of RILI.6
The first precedes clinical manifestation of RP and is char-
acterized by cell death with sloughing of type I pneumocytes
and endothelial cells, release of surfactant, fibrin exudation in
alveoli, decrease in macrophage counts, and occurrence of
interstitial edema. The second step marks acute RP and is
characterized by tissue reaction and inflammation with hy-
perplasia of type II pneumocytes; increase in leukocyte,
macrophage, and fibroblast counts; obstruction of endothelia;
and increase in collagen and elastin connective tissue fibers.
Finally, PF shows generalized fibrosis with loss of capillaries,
thickening of alveolar septa, and narrowing of alveoli.
There is no standardized approach in scoring RILI. The
criteria considered significant—absence or presence of symp-
toms, required treatment, and radiographic changes in the
lung—vary from one scoring system to another, making
evaluation of RILI ambiguous. Many scoring systems use the
need for medical intervention to score RP. For instance,
according to the Southwest Oncology Group,7 patients with
grade 2 RP need steroids, whereas patients with grade 3
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require oxygen. In contrast, according to Radiation Therapy
Oncology Group scoring,8 patients with grade 3 RP require
administration of both steroids and oxygen. LENT-SOMA
classification9 and the Common Toxicity Criteria version 210
include pulmonary function tests. All these scoring systems
also use radiographic changes (pulmonary fibrosis) as part
of their assessment. This variation in selection of scoring
criteria limits accuracy of RILI assessment11 as well as
making risk probability modeling based on diverse clinical
data problematic.12
Five-year survival rates of approximately 15% for lo-
cally advanced non-small cell lung cancer (NSCLC)13,14 and
20% for limited-disease small cell lung cancer (SCLC)15–17
are arguments in favor of treatment intensification, which is
severely hampered by RILI. Discrimination of patients at
high and low risk of RILI could facilitate dose escalation to
the tumor at the same or lower level of normal tissue com-
plication probability (NTCP) and allow inclusion of novel
drugs and radiation modalities in the treatment schedules.
Current population-based risk assessment relies on factors
that are related to the patient (age18; gender, race, smok-
ing19,20; comorbidity [impaired vascularity, chronic obstruc-
tive pulmonary disease, preexisting fibrotic diseases] or treat-
ment [chemotherapy {CT}21–23]; total radiation dose,24 the
dose per fraction,25 irradiated lung volume26,27).
Changes in pulmonary function tests (forced expiratory
volume in 1 second (FEV1), forced vital capacity [FVC],
carbon monoxide diffusion capacity [DLCO]) are used as
measures of RILI.28 Currently, pulmonary function tests are
rarely used to assess the risk of RILI because many patient-
specific factors influence these tests,29 reducing their predic-
tive value.30 Pulmonary dysfunction assessed with spirometry
tests (FEV1, FVC) might be small31 or partially improve with
time, particularly in patients with no preexisting pulmonary
disease32 unless there is pretreatment chronic obstructive
pulmonary disease– or chemotherapy-associated decline in
pulmonary function29,33 or pulmonary fibrosis develops.34
The one exception is postradiotherapy changes in DLCO,
which have been found to have a more predictable decrease
over time than FEV1 and FVC, suggesting its potential for
risk prediction of RILI.35
In current clinical practice, indices related to physical
absorbed dose (dosimetric parameters of radiotherapy) are
used to assess radiotherapy treatment plans and risk of RILI.
It is the purpose of our review to discuss the value of
existing dosimetric parameters of radiotherapy and biological
factors that might be used for the prediction of RILI in
individual patients. Such individual risk profiles remain a
challenge as current risk predictors are derived mainly from
population estimates. It is expected that radiation dose may
be increased by 30 to 40 Gy in patients at low risk of RILI if
their individual risk profiles are safely established.36
INDICES RELATED TO PHYSICAL ABSORBED
DOSE (DOSIMETRIC PARAMETERS OF
RADIOTHERAPY)
Dosimetric parameters used to predict the risk of RILI
comprise mean lung dose (MLD, i.e., the average dose in the
CT-defined total lung volume excluding the gross tumor
volume), the relative volume (in %) of the lungs receiving at
least the indicated dose in Gy (V[dose]), and normal tissue
complication probability (NTCP).
Three-dimensional radiotherapy planning allows accu-
rate computation of the dose distributions throughout the
organ and, thus, a thorough analysis of dose-volume relation-
ships. Table 1 shows selected literature data about the corre-
lation between dosimetric parameters describing lung dose-
volume relationship as expressed in dose-volume histograms
and incidence of RILI. Observed differences in NTCP, MLD,
V20, and V30 in patients with and without RP suggest the use
of these parameters as treatment planning objectives in tho-
racic radiotherapy. The optimal treatment plan should ensure
delivery of the planned high dose to the target at low com-
plication probability. It is, however, obvious from Table 1
that RP occurs even at low values of dosimetric parameters.
Dosimetric parameter–based dose escalation studies of radio-
chemotherapy are typically limited to 20% to 30% incidence
of symptomatic RP, which translates to approximately 5% of
patients exposed to life-threatening toxicity. In a systematic
review of dosimetric parameters, Rodrigues et al.37 reported high
rates of RP when MLD, V20, V25, V30, and NTCP predicted
low risk of RILI. The false-negative rates were 19% to 36% for
MLD, 25% to 50% for V(dose), and up to 44% for NTCP. Their
negative predictive values were only 60% to 80%.
Variations in treatment plans and scoring criteria for
NTCP may influence the outcome of different predictive
models.12,38 For example, MLD was found significantly bet-
ter (p  0.03) than V(dose), but factors used in the calcula-
tion of both parameters were not independent.38 Furthermore,
predictive models are influenced by the accuracy of the dose
calculation algorithms. Simplified calculation algorithms that
do not take into account the low density of the lung tissue,
tissue heterogeneity (lung-tissue, bone-tissue, air cavities),
and loss of electronic equilibrium overestimate dose in the
lung39 and force NTCP models to use less correct input
data.40 The use of advanced dose computation methods such
as convolution/superposition algorithms and Monte Carlo
dose engines in lung cancer treatment planning might im-
prove dose calculation and prediction of RILI.41
Tumor location and risk of RP were correlated in 99
patients with lung cancer.42 Higher rates of RP were observed
in patients with tumors in lower lobes, regardless of dosimet-
ric parameters. This was confirmed in the retrospective study
of 60 lung cancer patients treated with chemoradiotherapy, in
which irradiation of lower lung regions resulted in 70%
incidence of RP compared with 20% at other sites.43 Further
studies on regional radiosensitivity demonstrated difference
in predictive value of MLD for different lung regions.44–46
The observed discrepancy might be explained by higher
perfusion in the lower lobes making them more radiosensi-
tive, greater respiratory motion in lower lobes,47 resulting in
larger volumes irradiated44 as well as partial irradiation of the
heart that might also contribute to a higher risk of RP in the
lower lobes.48
Combination with chemotherapy complicates predic-
tion of RILI by dosimetric parameters (Table 1). Taghian et
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al.49 suggested a reduction of either the total radiation dose or
the lung volume by 24% in patients with breast cancer treated
with paclitaxel and radiation to lower the risk of RP to 1%.
Thus, combination of concurrent and/or inductive chemother-
apy and radiotherapy necessitates re-evaluation and valida-
tion of dosimetric parameters.50
A role of single-photon emission computer tomography
(SPECT) lung perfusion in RILI prediction has been stud-
ied.51–53 Marks et al.54 calculated dose-function-volume his-
tograms by correlating pretreatment CT data with SPECT
data. Prediction of RP based on SPECT data dose-volume
histograms was not superior to standard dose-volume histo-
grams, nor was the overall predictability of RILI improved
when receiver operating characteristic curves, a plot of the
true-positive rate versus the false-positive rate, were applied
to evaluate SPECT perfusion-based dose-function histo-
grams. Interestingly, in the subgroup of patients with pre-
treatment DLCO 40%, SPECT-based dosimetric parameters
were more predictive than the CT-based ones. Despite the
potential benefit of integrating functional variables into pre-
dictive models,55 the latter has not yet become a standard
practice.
BIOMARKERS
Interleukins (ILs)
Understanding the molecular mechanisms of radia-
tion-induced injury could make toxicity prediction patient-
specific and thus initiate a new paradigm in prediction of
RILI. Proinflammatory, profibrotic, and proangiogenic cy-
tokines have been implicated in RP and PF.56 Some of
these cytokines have been considered as potential markers
for RILI in humans including interleukin (IL)-1, IL-6,
and IL-8.57–61
IL-1 and IL-6 plasma levels were assessed prospectively
in a series of 31 patients with lung cancer and thymoma.62
Negative predictive value of IL-1, measured before and
throughout radiotherapy, was 50%, whereas it was slightly
higher for IL-6, with the highest negative predictive value of
54% for levels at 3 weeks of radiotherapy. The authors were
unable to show high negative predictive values of IL-1 and
IL-6 that would help to discriminate patients at low risk of RP
who could benefit from dose escalation.
Another prospective study followed 90 patients with
NSCLC. Changes in IL-6 plasma levels after 2 weeks of
treatment were significantly correlated with the occurrence of
RP seen at 6 to 8 weeks after the end of radiotherapy (p 
0.025).59 That correlation did not hold for RP seen at 6
months despite the putatively sustained character of RP,
suggesting differences in the involvement of IL-6 during
early and late stages of RP.
In a commercial multiplex suspension bead array sys-
tem covering 17 proinflammatory cytokines, a fourfold in-
crease in median IL-8 plasma levels was found in patients
without symptomatic RILI (SRILI) compared with those
TABLE 1. Indices Related to Physical Absorbed Dose (dosimetric parameters of radiotherapy)
Dosimetric Parameter RILI
Patient No.
Total (CT)Type Value
Incidencea
(%) Score Endpointb Ref.
MLDc (Gy) 15, 17.5–20, 22.5–25, 27.5 0, 13, 21, 43 RTOG RP (all) 66 (15) Oetzel et al., 1995128
0–8, 8–16, 16–24, 24–36 5, 11, 18, 43 SWOG RP (2) 540 Kwa et al., 1998129
20, 20 8, 24 RTOG RP (2) 99 (42) Graham et al., 1999130
10, 10–20, 21–30, 30 10, 16, 27, 44 CTC v.2.0 RP (all) 201 (121) Hernando et al., 2001131
V10 (%) 33 53 LENT-SOMA RP (1) 96 (63) Claude et al., 2004132
V20 (%) 22, 22–31, 31%–40 0, 7, 13 RTOG RP (2) 99 (42) Graham et al., 1999130
25, 26, 32 14, 63, 32 CTC v.2.0 RP (2) 71 (71) Tsujino et al., 2003133
18 56 96 (63) Claude et al., 2004 132
V25 (%) 30, 30 4, 38 RTOG RP (3) 31 Armstrong et al., 1995134
V30 (%) 18, 18 6, 24 CTC v2.0 RP (all) 201 (121) Hernando et al., 2001131
13 56 96 (63) Claude et al., 2004132
V40 10 56 96 (63) Claude et al., 2004132
V50 5 53 96 (63) Claude et al., 2004132
Lyman NTCPc 1st, 2nd, 3rd, 4th quartiles 0, 5, 14, 29 SWOG RP (1) 42 Martel et al., 1994135
1st, 2nd, 3rd, 4th quartiles 10, 18, 16, 33d CTC v2.0 RP (all) 201 (121) Hernando et al., 2001131
Kutcher NTCP (%) 12, 12 0, 29 RTOG RP (3) 31 Armstrong et al., 1995134
1st, 2nd, 3rd, 4th quartile 29, 12, 29, 38 In-house RILI 100 (30) Marks et al., 199754
NTCP (%) 30, 30 10, 29 RTOG RP (all) 66 (15) Oetzel et al., 1995128
CT, chemotherapy; CTC, Common Toxicity Criteria; MLD, mean lung dose; NTCP, normal tissue complication probability; RILI, radiation-induced lung injury comprising RP
and pulmonary fibrosis; RP, radiation pneumonitis; RT, radiotherapy; RTOG, Radiation Therapy Oncology Group; SCLC, small cell lung cancer; SWOG, Southwest Oncology Group;
V10, V20, V25, V30, V40, and V50, the relative volume (in %) of the lungs receiving at least 10, 20, 25, 30, 40, and 50 Gy, respectively.
a Incidence of RILI.
b Grades are in parentheses.
c Lungs analyzed as separate organ.
d Average observed probabilities.
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developing SRILI and healthy controls: 1.49 pg/ml versus
0.34 pg/ml and 0 pg/ml (p 0.001).60 The proposed negative
predictive value of 91.1% was based on assumptions of a
SRILI incidence of 15% and preradiotherapy IL-8 plasma
level of more than 1.2 pg/ml. The retrospective character of
the study, patient selection criteria (availability of plasma
samples),and uncertainty between authors’ assumptions of
incidence of SRILI and its incidence in the subset of studied
patients (of 55 patients, 22 patients had SRILI) weaken the
conclusions about the correlation between IL-8 levels and
SRILI.
Biomarkers Other than ILs
Molecules, other than ILs, have also tested as RP
predictors, such as soluble intercellular adhesion molecule-1
(sICAM-1), mucin-like glycoprotein antigen KL-6, cytoker-
atin 19 fragment (CYFRA 21-1), pulmonary surfactant pro-
teins A (SP-A) & D (SP-D), and transforming growth factor
1 (TGF-1).
In a group of 30 patients with lung malignancies,
levels of sICAM-1 were significantly elevated in the RP
patients compared with baseline levels (p  0.05).63 Ele-
vation started in the middle of treatment and reached peak
values when RP became clinically evident. However, the
time between the end of radiation therapy and the onset of RP
was too short for treatment modification, making sICAM-1
less useful clinically.
Antigen KL-6 against human lung adenocarcinoma64 was
monitored in lung cancer patients receiving radiotherapy.65,66
KL-6 appeared to be a useful marker for detecting severe
pneumonitis and estimating its prognosis. In breast cancer
patients who underwent adjuvant radiotherapy,67 posttreat-
ment serum levels were significantly different in patients with
and without RP (p  0.0421). In patients with primary and
metastatic lung tumors who received single fraction stereo-
tactic radiotherapy,68 the ratio of month 2 posttreatment and
baseline levels significantly correlated (p  0.04) with the
occurrence of RP. The 1- to 2-month gap between time of the
most predictive measurements and diagnosis of RP, however,
limits the predictive value of KL-6.
Serum levels of CYFRA 21-1, a marker of lung can-
cer,69–71 were found to be elevated in lung cancer patients
with diffused RP compared with those with local pneumonitis
and healthy smokers without cancer (p  0.002).72 Increase
in CYFRA 21-1 serum levels also correlated with the clinical
course of RP, pointing to its value as a marker of existing RP
but less so as a predictor.
Prospective investigation of SP-A and SP-D in the
serum of 25 patients with thoracic malignancies before and
1 week after radiotherapy showed a high negative predic-
tive value for RP of 85%.73 However, blood sampling and
RP scoring were performed at the same time, at week 1 after
the end of radiation therapy. Sasaki et al.74 confirmed the
usefulness of SP-A and SP-D in early detection RP. Serum
levels of SP-D were significantly increased at all time points
(before, during RT, and throughout follow-up) in patients
with RP (p  0.001) with the highest level at the occurrence
of RP (p  0.001). Of 19 patients developing RP, RP
occurred in 11 patients during treatment or within 1 month
after its completion. Therefore, although SP-A and SP-D may
act as biomarkers for RP, they probably will not be good RP
risk predictors.
TFG-1
TGF-1 plays a key role in tissue response to radio-
therapy75 as a master switch for development and persistence
of fibrosis.76 Ionizing radiation induces the release of TGF-1
from a latent complex (activation of TGF-1) that can occur
at radiation doses as low as 0.5 Gy77 (Figure 1). Pretreatment
plasma levels of TGF-1 were elevated in 53% of lung
cancer patients; median pretreatment levels of TGF-1 were
lower in patients who developed RP (median, 6.5 ng/ml)
compared with those without RP (9.0 ng/ml), suggesting that
higher pretreatment levels did not predispose to RP.61 Nev-
ertheless, relative changes in the biomarker levels at the
beginning and the end of radiotherapy were higher in patients
with RP (1.13  0.33) compared with those without RP (0.7 
0.15). Changes in the cytokine levels during treatment appeared
to discriminate between patients at low and high risk of RP.
The feasibility of using TGF-1 levels to select patients
for dose escalation was tested in 38 patients with NSCLC.78
At the end of the initial radiation treatment, patients with
TGF-1 levels lower than pretreatment levels and patients
with TGF-1 levels7.5 ng/ml were selected for subsequent
dose escalation (86.4 Gy versus 73.6 Gy) in the primary
tumor and enlarged lymph nodes. Predominant severe (grade
3) late toxicity was not pulmonary but esophageal. Molec-
ular mechanisms of radiation-induced esophageal injury
might be partially related to those of RILI. Monitoring plasma
levels of TGF-1 might be used for selecting patients resistant to
both RILI and radiation-induced esophageal toxicity.
A cohort of 78 patients with lung cancer were, retro-
spectively, classified into low-, intermediate-, and high-risk
groups pending upon V30 and TGF-1 kinetics.79 The latter
combination showed a better correlation with SRILI than
each of the parameters alone. Risk of RILI was significantly
higher (p  0.008) in patients with increased postradio-
therapy TGF-1 plasma levels and V3030%. The results of
this study are encouraging; however, the retrospective nature
of the study, the inhomogeneous patient population (different
radiotherapy dose regimens, previous chemotherapy and sur-
gery) and the use of only one physical parameter suggest that
further investigations are needed to demonstrate the predic-
tive capabilities of TGF-1.
In 68 patients with NSCLC, De Jaeger et al.80 found
elevated (20 ng/ml) pretreatment TGF-1 levels in 51% of
the cases. TGF-1 plasma levels at the end of radiotherapy
were associated with pretreatment levels (p  0.001) and
with MLD (p  0.001). The average ratio of plasma levels at
weeks 4 to 6 of treatment over pretreatment levels signifi-
cantly predicted RP according to Southwest Oncology Group
criteria (p  0.01) but not other scoring systems. The high
TGF-1 baseline values, possibly due to methods of blood
collection and processing attracted major criticism.81,82
In another prospective study of 46 patients with
NSCLC, using the same methodology, the difference in ratio
of TGF-1 plasma levels at week 3/pretreatment between
patients with and without symptomatic RP was only margin-
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ally significant (p  0.055).83 The authors did not advocate
TGF-1 as a predictor of RP in the lung treated by radio-
therapy.
The interindividual variation in TGF-1 levels and
the corresponding radiosensitivity may be the result of
single nucleotide polymorphisms (SNPs) in the TGF1
gene.
SNPs IN TGF-1
SNPs represent the most abundant type of sequence vari-
ation in the human genome. Currently, increasing efforts are
made to investigate whether this widespread type of genetic
germline variation influences a variety of oncology related
phenotypes such as cancer susceptibility, disease outcome, and
treatment response. The involvement of SNPs in normal tissue
complications after radiotherapy treatment is also being exten-
sively studied.84
The mechanisms by which SNPs affect phenotype
and influence complex diseases vary according to their
genomic location. Substitutions in coding regions may
affect the amino acid sequence of predicted proteins,
reducing or abolishing functions like DNA binding, cata-
lytic activity, and receptor-ligand contact. SNPs may in-
terrupt the initiation or the termination codon or introduce
errors in the reading frame shift, all with consequences
FIGURE 1. Transforming growth factor 
(TGF-) Smad signaling pathway. TGF- binds to
transmembrane serine/threonine kinases: TGF-
type I and II receptors (TGF RI and TGF RII).
There exists a TGF- type  receptor (not
shown) that promotes binding of TGF1 to TGF
RII. TGF RII phosphorylates TGF RI leading to
activation of downstream proteins Smad2 and
Smad3. The latter are kept in the cytoplasm by
binding to SARA (Smad anchor for receptor acti-
vation). Phosphorylation of Smad2 and Smad3
increases their affinity for Smad4 resulting in the
formation of heteromeric complexes Smad2/
Smad4 and Smad3/Smad4. These complexes are
translocated into the nucleus and act as transcrip-
tional modulators (coactivators and corepressors)
in cell type–specific and ligand dose–dependent
manner. Although the Smad pathway is not the
only TGF-1 signaling pathway,115–117 it mediates
most profibrotic activities mainly by Smad3.118,119
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for insufficient or prematurely truncated peptides. SNPs
located in regulatory regions may influence gene expres-
sion, whereas SNPs in noncoding sequences may affect
splicing or RNA cleavage, stability, and export.85
Several observations indicate that normal tissue hy-
persensitivity may be related to genetic factors.86,87 Until
now, a large number of studies have reported a possible
correlation between SNPs and clinical normal tissue radi-
osensitivity in patients.88–90 Candidate genes comprised
generally genes encoding proteins of DNA repair and
DNA response pathways. Although several studies showed
highly significant associations between clinical radiosen-
sitivity and SNPs in DNA repair genes,91–93 the strongest
associations with normal tissue reactions after radiother-
apy were found with polymorphisms in the TGF1
gene.94–96 The latter studies dealt with breast cancer and
gynecologic cancer patients with late fibrosis associated
complications after radiotherapy treatment.
Grainger et al.97 demonstrated that the TGF1 pro-
moter genotype is responsible for 54% of the variation in
plasma levels of TGF-1. They studied the 800GA and
509CT polymorphisms and found that the homozygote
variant 509TT genotype was significantly associated
with increased serum levels of TGF-1. The Leu10Pro and
the Arg25Pro polymorphisms in exon 1 of the TGF1 gene
are located in the signal peptide sequence that is cleaved
from the TGF1 precursor at codon 29. For these poly-
morphisms, several research groups have reported that the
interindividual differences in TGF-1 production can also
be a consequence of polymorphisms in the coding regions
of the TGF1 gene. Dunning et al.98 showed in in vitro
experiments that the allele encoding the variant 10Pro
amino acid is associated with increased rates of TGF-1
secretion. Yokota et al.99 reported that the amount of
TGF-1 in serum is higher for variant 10Pro homozygotes
than for wild-type 10Leu homozygotes. For the Arg25Pro
polymorphism, however, homozygosity for the normal
25Arg allele is associated with higher TGF-1 production
in vitro.100
Previously published studies addressing the influence
of TGF1 polymorphisms on clinical radiosensitivity es-
tablished significant associations between the Leu10Pro
and 509CT polymorphisms and increased risk of radi-
ation-induced late complications following RT for breast
cancer and cervix or endometrial cancer.89,92–94 This asso-
ciation was most pronounced92 or retrieved only89,94 when
the mutant homozygous genotype was compared with the
wild-type genotype. Linkage analysis of the studied polymor-
phisms showed a strong linkage between the 509CT and
Leu10Pro polymorphisms. Recently, De Ruyck et al.96 showed
that there exists a perfect linkage between the 1.552delAGG
and the 509CT polymorphisms. The effect on clinical
radiosensitivity and TGF-1 plasma levels reported in the
literature could thus be caused as well by the Leu10Pro
polymorphism by its influence on the intracellular traffick-
ing or export efficiency of the propeptide and by the
1.552delAGG or the 509CT polymorphism through
their effect on the production of the proprotein.
DISCUSSION
Multiple factors influence the response of tissues to
ionizing radiation and the development of RILI. Among those
factors are genetic and epigenetic background of the patient,
the characteristics of the radiation and other treatments, and
the cellular and molecular events occurring in the irradiated
ecosystem and in its systemic connections. RILI-associated
factors appear to be multifold, some being relatively stable
(physical characteristics of ionizing radiation) and others
highly dynamic (cellular and molecular changes, their cross-
talks and signaling networks). We would expect these
changes to be detectable in both the irradiated tissues and the
entire organism, including body fluids.
As an example, let us examine TGF-1. It is evident
from experimental observations, including cell cultures and
transgenic animals, that TGF-1 is a major regulator of
radiation-induced or other fibrosis. Therefore, it has long
been considered as a paradigm biomarker for RILI. However,
a major concern with all studies that measure TGF-1 levels
is whether the plasma levels of TGF-1 as measured in the
studies truly reflect the amount/activity of this cytokine in the
irradiated lung. Large variations in baseline levels (between 2
and 20 ng/ml) cast doubt on the methodologies used in the
studies. Excessive platelet degranulation by freezing plasma
and during long centrifugation is a major pitfall.101 In sam-
ples that are macroscopically hemolytic, TGF-1 levels are
approximately 10 times higher than in most other samples
(our unpublished results obtained by enzyme-linked immu-
nosorbent assay, Quantikine R & D Systems, Abingdon,
U.K.). Various blood cells such as platelets, leukocytes, and
erythrocytes are rich sources of TGF-1 and its release into
the serum might be caused not only by the method of
collection but also by pathological conditions of these cells.
Comorbidity such as asthma,102 chronic obstructive pulmo-
nary disease,103 hypertension,104 diabetes,105 and obesity106
may change the level of TGF-1 per se or the release of the
cytokine from blood cells during the sampling and prepara-
tion of the plasma. In association with type 1 diabetes,
smoking increased serum levels of TGF-1,107 although
smoking alone might have a lung-protective effect in patients
receiving thoracic radiotherapy.108 Tamoxifen might induce pro-
duction of TGF-1 and result in higher incidence of PF.109
Other candidate biomarkers are highly probable and
worth searching for. They may depend on radiation-induced
activation of TGF-1. Considering TGF-1 as the initiator of
RILI, the complexity of its signaling (Figure 1) and the
variety of cellular activities affected (Figure 2) necessarily
implicate a large number of molecules, some of which might
be released into the circulation and serve as possible biomar-
kers. For example, transition from fibroblasts to myofibro-
blasts implicates changes in a large number of proteins as
evidenced by comparative two-dimensional gel electrophore-
sis.110 The latter finding is in line with the multiplicity of genes
targeted by TGF-1–mediated Smad signaling (Figure 1). Next
to TGF-1, proinflammatory cytokines, such as tumor necro-
sis factor , IL-1, and IL-6, may serve as initiators because
they are produced by the bronchiolar epithelium, detectable
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within the first hours after irradiation,111 and also signal
multiple target genes.
Radiogenomics with genotyping analysis of SNPs in
TGF1, in TGF-1 pathway genes, and in other proinflam-
matory cytokines may allow the identification of genotypes
prone to RILI. Because low penetrant genetic modifications
affect complex diseases through the joint effect of single
modifications of gene-influencing TGF-1 levels may con-
tribute to the predisposition of radiation response, it has been
demonstrated that disruption of the TGF-1 signal transduc-
tion pathway using Smad3 null mice results in resistance to
radiation-induced fibrosis.112 An antifibrotic effect was also
observed after overexpression of the inhibitory Smad7 pro-
tein in mice.113 Overexpression of the type II TGF-1 recep-
tor in rats was shown to be protective against radiation-
induced injury in the lung.83 SNPs in these signal
transduction pathway genes could result in modified protein
levels and influence TGF-1 signaling and radiation re-
sponse.
Radiation-induced molecular signals come in waves
with clear-cut differences between early and late phases of
normal tissue complications.114 Therefore, regardless of the
nature of the putative biomarker, studying the kinetics of
biomarkers is of great importance.
Why has the ideal biomarker not been yet found? We
hypothesize that the combination of biological factors and
physical parameter models will allow the construction of a
patient-specific risk profile. So far, the molecules that have
been tested as biomarkers of RILI failed to show a high
negative predictive value and can, therefore, not be used as
independent predictors. Taking TGF-1 plasma levels as a
paradigm, the following observations might explain this
failure:
1. Studies that are hard to compare and formulate general
patterns: prospective versus retrospective, differences in
patient cohorts studied (e.g., tumor site, preceding chemo-
therapy and surgery, different fractionation schedules of
radiotherapy; different data analysis applied)
2. Uncertainties in scoring RILI using different scoring sys-
tems such as those of the Radiation Therapy Oncology
Group, Common Toxicity Criteria, LENT-SOMA, the
Southwest Oncology Group classification and different
grades of toxicity considered significant
3. Variations in methodology for proceeding blood samples
and detecting plasma levels of the cytokine
4. Not taking into account genetic predisposition and com-
plexity of RILI pathogenesis and its underlying molecular
mechanisms.
It might be useful to reconstruct the “ideal” experiment
that would omit possible pitfalls and shortcomings encoun-
tered in the previous work and that might lead to more
predictive results. Before initiating the study, a strict study
protocol should be thoroughly designed and written in detail.
To ensure detecting changes in biomarker levels before the
occurrence of RP when early treatment intervention is pos-
sible, blood samples should be collected before, throughout,
and at the end of radiotherapy. Moreover, absolute pretreat-
ment levels of the biomarker are unlikely to have any pre-
dictive value; therefore studying its dynamics is essential.
FIGURE 2. Transforming growth factor 1 (TGF-1) in the irradiated ecosystem. TGF-1 is produced by virtually all types of
cells. It is released and stored mostly in extracellular matrix as inactive, complex, noncovalently associated with latency-associ-
ated peptide (LAP) and the latent TGF-1 binding protein 1 forming latent TGF- (LTGF ).120 Reactive oxygen species (ROS)
generated almost immediately after exposure to ionizing radiation121 cause oxidation of specific amino acids followed by con-
formational changes in the latent complex and release of TGF-1.122 Because of that unique redox activation, TGF-1 is con-
sidered a sensor and signal of oxidative stress.114 Chemotherapeutic agents such as cis-platinum123 or alkylating agents124 also
activate TGF-1. The protease subtilisin-like pro-protein convertase is a natural activator of TGF-1.125 In the cancer ecosys-
tem, activated TGF-1 mediates epithelial apoptosis (), mesenchymal proliferation with transition of fibroblasts into myofi-
broblasts,120 recruitment of inflammatory cells (monocytes),126 and remodeling of extracellular matrix through production of
collagen (COLL) and breakdown via matrix metalloproteinases (MMP).127 Blue strike, ionizing radiation.
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One should opt for a commercial assay that includes a
standard curve and appropriate controls. A second assay
might be used to confirm the values obtained. The most
important point is the examined material. A checklist for
proper sampling, preparation of plasma through stepwise
centrifugation, and storage is an essential part of the study
protocol. Additional tests determining markers for platelet
degranulation should be performed. The patients’ condition at
the moment of sampling should be noted. The study would
also need quality control. It is possible that a better biomarker
may be found as a by-product. So, to keep the list of
candidates open, not only plasma but serum should be taken
too, for some molecules of interest are degraded in the
absence of calcium. RILI as an endpoint needs strict defini-
tion of criteria with emphasis on timing. Sensitivity, speci-
ficity, and positive and negative predictive value should be
reported.
Better understanding of the molecular and cellular
mechanisms of RILI including genetic variability may help to
identify effective predictive markers and thus improve risk
prediction and individualize treatments. Individual pheno-
type- and genotype-based risk profiles would allow the iden-
tification of patients who could benefit from dose escalation
in chemoradiotherapy while keeping the rate of RILI the
same or even lower.
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